Testing an Educational Program to Improve Goals of Care Conversations Between Patients and Their Care Teams
NCT ID: NCT07278739
Last Updated: 2025-12-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
NA
1020 participants
INTERVENTIONAL
2026-05-03
2032-07-21
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Telephone-Based Coaching Sessions (TAC) to Improve Advance Care Planning Participation in Advanced Cancer Patients and Their Caregivers
NCT07141407
RCT of QPS vs General Information Sheet
NCT03287492
Web-Based Tailored Educational Program in Improving Nurse Communication With Patients About Clinical Trials
NCT02129517
Computer Program in Improving Communication Between Doctors and Patients With Stage IV Cancer
NCT00276627
TeamTalk: Improving Inter-professional Communication During Cancer Treatment
NCT07083674
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
I. To compare the proportion of participants who have any hospitalizations within 12 months after randomization between those receiving A-PACT (intervention arm) and those receiving usual care alone (control arm).
SECONDARY OBJECTIVES:
I. To compare the proportion of participants who report anxiety at 3 months compared to baseline between participants receiving A-PACT and participants receiving usual care.
II. To compare the proportion of participants who report depression at 3 months compared to baseline between participants receiving A-PACT and participants receiving usual care.
III. To assess the proportion of participants who receive intensive end-of-life care between participants receiving A-PACT and those receiving usual care alone.
IMPLEMENTATION OBJECTIVES:
I. To quantitatively and qualitatively assess how patient, clinician, and organizational factors shape effectiveness and implementation of A-PACT.
II. To measure feasibility of machine learning (ML) algorithm, adoption of intervention (patient enrollment), and fidelity (% of patients completing A-PACT).
EXPLORATORY OBJECTIVES:
I. To assess the following in participants on the intervention arm versus the usual practice arm:
Ia. The proportion of participants who have any hospitalization or emergency department visits within 12 months from randomization between those receiving A-PACT and those receiving usual care; Ib. The mean number of hospitalizations within 12 months from randomization between participants receiving A-PACT and participants receiving usual care alone; Ic. The mean number of hospitalizations or emergency department visits within 12 months of randomization between participants receiving A-PACT and participants receiving usual care alone; Id. Anxiety at 6 months from baseline; Ie. Depression at 6 months from baseline; If. Heard and Understood measures at 6 months from baseline; Ig. Prognostic awareness and treatment preferences at 6 months from baseline; Ih. Presence of goals of care documentation in the electronic health record at 12 months; Ii. Presence of advance directive documentation in the electronic health record at 12 months; Ij. Presence of physician orders for life sustaining treatment documentation in the electronic health record at 12 months; Ik. The potential differential impact of sociodemographic factors on all outcomes.
OUTLINE: Patients are randomized to 1 of 2 groups.
GROUP 1: Patients attend an initial A-PACT education session over 30-45 minutes by phone and receive follow-up A-PACT phone calls over 15 minutes each twice monthly, or less frequently per patient preference, for up to 6 months, in addition to usual care.
GROUP 2: Patients receive usual care for 6 months.
After completion of study intervention, patients are followed up at months 9 and 12.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
HEALTH_SERVICES_RESEARCH
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group 1 (Usual care + A-PACT)
Patients attend an initial A-PACT education session over 30-45 minutes by phone and receive follow-up A-PACT phone calls over 15 minutes each twice monthly, or less frequently per patient preference, for up to 6 months, in addition to usual care.
Best Practice
Receive usual care
Educational Intervention
Receive A-PACT education
Electronic Health Record Review
Ancillary studies
Interview
Ancillary studies
Questionnaire Administration
Ancillary studies
Telephone-Based Intervention
Receive A-PACT phone calls
Group 2 (Usual care)
Patients receive usual care for 6 months.
Best Practice
Receive usual care
Electronic Health Record Review
Ancillary studies
Questionnaire Administration
Ancillary studies
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Best Practice
Receive usual care
Educational Intervention
Receive A-PACT education
Electronic Health Record Review
Ancillary studies
Interview
Ancillary studies
Questionnaire Administration
Ancillary studies
Telephone-Based Intervention
Receive A-PACT phone calls
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Participants must be identified as high risk, defined as having 6 month mortality estimate from machine learning (ML) algorithm \>= 20%
* Participants must not be receiving or have pre-existing plans to enter hospice care at the time of study registration
* Participant must be actively receiving or planning to receive systemic anti-cancer therapy (defined as any oral, injection, or intravenous therapy against cancer) within 3 months after registration
* NOTE: This includes chemotherapy (conventional or cytotoxic chemotherapy), hormone therapy, targeted therapy, and immunotherapy
* NOTE: Participants are allowed to be co-enrolled on other clinical trials including trials using investigational agents
* Participants must be \>= 18 years of age at the time of study enrollment
* Participants who can complete Patient Reported Outcome (PRO) questionnaires in English or Spanish must be willing to 1) complete PROs at all scheduled assessments; and 2) complete the pre-registration (baseline) PRO forms within 14 days prior to registration
* Participants must be able to provide a valid telephone number for the purpose of being contacted by the lay health worker
* NOTE: As a part of the Oncology Patient Enrollment Network (OPEN) registration process the treating institution's identity is provided in order to ensure that the current (within 365 days) date of institutional review board approval for this study has been entered in the system
* Patient and clinician participants must be informed of the investigational nature of this study and must sign and give informed consent in accordance with institutional and federal guidelines. This protocol does not permit use of Legally Authorized Representative NOTE: For this study, in the OPEN registration, clinician participants will be listed as their own treating investigator. However, clinician participants must not consent themselves or sign their own eligibility criteria forms
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Cancer Institute (NCI)
NIH
SWOG Cancer Research Network
NETWORK
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ravi B Parikh
Role: PRINCIPAL_INVESTIGATOR
SWOG Cancer Research Network
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NCI-2025-08258
Identifier Type: REGISTRY
Identifier Source: secondary_id
S2424CD
Identifier Type: OTHER
Identifier Source: secondary_id
SWOG-S2424CD
Identifier Type: OTHER
Identifier Source: secondary_id
S2424CD
Identifier Type: OTHER
Identifier Source: secondary_id
S2424CD
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.